论文部分内容阅读
目的:探讨声频共振联合全身应用激素及常规药物治疗突发性聋(SHL)的近期及远期疗效。方法:将128例SHL患者随机分为对照组(60例)和声频组(68例)。对照组予以全身激素及常规药物治疗;声频组在对照组治疗的基础上,予以声频共振联合外耳道灌注药物(VitB1、VitB12、ATP)治疗。结果:治疗后2周,声频组总有效率为66.18%,对照组为65.00%;治疗后4周,声频组为72.06%,对照组为70.00%;治疗后8周,声频组为73.53%,对照组为68.33%。3个时期2组差异无统计学意义(P>0.05)。治疗后4周和8周,声频组平均听阈分别为(43.87±16.73)dB和(40.96±17.11)dB,明显低于对照组(50.89±18.41)dB、(48.93±17.84)dB(P<0.05)。治疗中均未出现严重不良事件。结论:应用激素及常规药物治疗可明显降低SHL患者听阈,且安全无明显不良反应,值得临床推广。
Objective: To investigate the short-term and long-term effects of audio resonance combined with systemic hormones and conventional drugs in the treatment of sudden deafness (SHL). Methods: 128 SHL patients were randomly divided into control group (60 cases) and audio group (68 cases). The control group was treated with systemic hormones and conventional drugs. On the basis of the treatment of the control group, the audio group was treated with the combination of external auditory meatal perfusion (VitB1, VitB12, ATP). Results: At 2 weeks after treatment, the total effective rate was 66.18% in the audio group and 65.00% in the control group. After 4 weeks of treatment, the audio frequency group was 72.06% and the control group was 70.00%. After 8 weeks of treatment, the audio group was 73.53% The control group was 68.33%. There was no significant difference in the three groups between the two groups (P> 0.05). The mean hearing threshold of audio group were (43.87 ± 16.73) dB and (40.96 ± 17.11) dB at 4 weeks and 8 weeks after treatment, respectively, which was significantly lower than that of control group (50.89 ± 18.41) dB and (48.93 ± 17.84) dB ). No severe adverse events occurred during the treatment. Conclusion: The application of hormones and conventional drugs can significantly reduce the hearing threshold of patients with SHL, and no significant adverse reactions, is worthy of clinical promotion.